Clinical Trial Search

Primary: Part 1: Number of Participants With Non-serious Adverse Events (AEs) and Serious Adverse Events (SAEs) — 7; 1; 2; 2 Participants

Primary: Number of Participants With Dose Limiting Toxicities (DLT) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD) — 0; 0; 2 participants

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 1; 0 Participants

Primary: Within-session Change in Percentage of "Correct" Ratings by Blinded Naive Listeners for /r/ Sounds Produced in Word Probes — 1.4; 1.9 Percent correct — p=.72

Primary: Maximum Tolerated Dose — 2.24 mg/m^2

Primary: Pyronaridine Pharmacokinetics: Tmax, Half-life — 0.184; 0.166; 14.2; 14.1 days

Primary: Pharmacokinetics Analysis: Half-life, Tmax — 384; 321.6; 2.32; 1.44 hours

Primary: Part 1: Mean Cumulative Amount of Total Radioactivity (CumAe) of [14C]-GDC-9545 Excreted in Urine, Feces, and Total (Urine and Feces Combined) Over the Entire Collection…

Primary: Subjects With Adverse Events (AEs) up to 3 Days Post-dosing — 3; 4; 6; 2 Participants

Primary: Part A: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Vaccine Regime — 1; 0; 2; 5 Participants

Primary: Within-person Change in Daily Steps. — 120.85; 257.42 Daily Steps

Primary: Maximum Tolerated Dose (MTD) or Recommended Phase 2 Dose (R2PD) of Entinostat — 4 mg/m²

Primary: Number of Participants With a Dose Limiting Toxicity (DLT), Triggered by Occurrence in the First 24 Hours After Human Mesenchymal Stem Cell (hMSC) Infusion of Grade ≥3…

Primary: Number of Participants With Grade 3 Adverse Reactions or Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 24 Hours After the First…

Primary: Part A, AUC∞: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity for Midazolam — 57.2; 42.1 hour*nanogram per milliliter (h*ng/mL)